Gastric and Gastroesophageal Junction Adenocarcinoma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029

1.1 Large Market Growth Forecast for the G/GEJAC Market During 2019-2029
1.2 BMS Set to Take Market-Leading Position
1.3 The Level of Unmet Need in the G/GEJAC Market is Set to Remain High
1.4 Increasing Interest in Developing Therapies for Niche Populations
1.5 Multiple Novel Therapies Set to Launch in Metastatic and Adjuvant Settings
1.6 What Do Physicians Think?

2.1 Catalyst - Market-Impacting Events Shaping Forecast Changes
2.2 Related Reports
2.3 Upcoming Reports

3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or Staging Systems

4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.3.1 8MM, Trends in the Diagnosed Incidence
4.4 Forecast Methodology
4.4.1 Sources
4.4.2 Forecast Assumptions and Methods
4.5 Epidemiological Forecast for Gastric Cancer (2019-2029)
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of the Analysis
4.6.4 Strengths of the Analysis

5.1 Diagnosis and Treatment Overview
5.2 US
5.3 Europe
5.4 Japan
5.5 South Korea
5.6 KOL Insights on Disease Management

6.1 Overview

7.1 Overview
7.2 Novel Drugs to Address Stage IV G/GEJAC Patients
7.3 Lack of Treatment Options for Patients with Stage II-III G/GEJAC in the Adjuvant/Neoadjuvant Setting
7.4 Demanding Evaluation of Cost-Effectiveness Impacting Approval and Reimbursement Across the 8MM
7.5 Disparity in Adoption of Nationwide Screening Programs Hinders Early-Stage Disease Diagnosis in the US and 5EU

8.1 Overview
8.1.1 The Development of HER2-Targeting Therapies with Novel MOAs
8.1.2 Investigation of Novel Immunotherapy Targets and Combinations with Targeted Agents
8.1.3 The Development of Novel Targets for Specific Populations
8.2 Clinical Trials Design
8.2.1 Use of Appropriate Agents in Comparator Arm in Trials
8.2.2 Use of Preferred Chemotherapy Regimens in Combination Treatment

9.1 Overview
9.2 Promising Drugs in Clinical Development

10.1 Overview
10.2 Competitive Assessment.

11.1 Overview
11.2 Deal-Making Trends

Table 1: G/GEJAC: Key Metrics in the 8MM
Table 2: Stage Definitions for Gastric Cancer
Table 3: Risk Factors for Gastric Cancer
Table 4: Treatment Guidelines for G/GEJAC
Table 5: Generic Chemotherapy Regimens Indicated for Gastric Cancer
Table 6: Top 10 Deals by Value, 2018-21
Table 7: G/GEJAC Market - Global Drivers and Barriers, 2019-29
Table 8: Key Events Impacting Sales for G/GEJAC in the US, 2019-29
Table 9: G/GEJAC Market - Drivers and Barriers in the US, 2019-29
Table 10: Key Events Impacting Sales for G/GEJAC in the 5EU, 2019-29
Table 11: G/GEJAC Market - Drivers and Barriers in the 5EU, 2019-29
Table 12: Key Events Impacting Sales for G/GEJAC in Japan, 2019-29
Table 13: G/GEJAC Market - Drivers and Barriers in Japan, 2019-29
Table 14: Key Events Impacting Sales for G/GEJAC in South Korea, 2019-29
Table 15: G/GEJAC Market - Drivers and Barriers in South Korea, 2019-2029
Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales Forecast by Country for G/GEJAC in 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in G/GEJAC During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that the Publisher Expects to be Licensed for the Treatment of G/GEJAC in the Adjuvant/Neoadjuvant Setting During the Forecast Period
Figure 4: Competitive Assessment of the Late-Stage Pipeline Agents that the Publisher Expects to be Licensed for the Treatment of G/GEJAC in the HER2-Positive Setting During the Forecast Period
Figure 5: Competitive Assessment of the Late-Stage Pipeline Agents that the Publisher Expects to be Licensed for the Treatment of G/GEJAC in the HER2-Negative Setting During the Forecast Period
Figure 6: 8MM, Diagnosed Incidence of Gastric Cancer, Men, Ages =20 Years, 2009-2029, Cases Per 100,000 Population
Figure 7: 8MM, Diagnosed Incidence of Gastric Cancer, Women, Ages =20 Years, 2009-2029, Cases Per 100,000 Population
Figure 8: Sources Used and Not Used for Diagnosed Incident Cases of Gastric Cancer
Figure 9: Sources Used for Diagnosed Incident Cases of Gastric Cancer by Stage at Diagnosis
Figure 10: Sources Used for Five-Year Diagnosed Prevalent Cases of Gastric Cancer
Figure 11: Sources Used for Diagnosed Incident Cases of Gastric Cancer with HER2 Overexpression
Figure 12: Sources Used for Diagnosed Incident Cases of Gastric Cancer with PD-L1 Expression
Figure 13: Sources Used for Diagnosed Incident Cases of Gastric Cancer with MSI
Figure 14: Sources Used for Diagnosed Incident Cases of Gastric Cancer with NTRK Gene Fusions
Figure 15: Sources Used for Diagnosed Incident Cases of GEJ Cancer
Figure 16: Sources Used for Diagnosed Incident Cases of Gastric Cancer, excluding GEJ Cancer
Figure 17: Sources Used for Diagnosed Incident Cases of Gastric Adenocarcinoma
Figure 18: 8MM, Diagnosed Incident Cases of Gastric Cancer, Men and Women, Ages =20 Years, 2019
Figure 19: 8MM, Age-Specific Diagnosed Incident Cases of Gastric Cancer, Men and Women, Ages =20 Years, 2019
Figure 20: 8MM, Sex-Specific Diagnosed Incident Cases of Gastric Cancer, Men and Women, Ages =20 Years, 2019, N
Figure 21: 8MM, Five-Year Diagnosed Prevalent Cases of Gastric Cancer, Men and Women, Ages =20 Years, 2019
Figure 22: 8MM, Diagnosed Incident Cases of Gastric Cancer by Stage at Diagnosis, Men and Women, Ages =20 Years, 2019
Figure 23: 8MM, Diagnosed Incident Cases of Gastric Cancer with HER2 Overexpression, Men and Women, Ages =20 Years, 2019
Figure 24: 8MM, Diagnosed Incident Cases of Gastric Cancer with PD-L1 Expression, Men and Women, Ages =20 Years, 2019
Figure 25: 8MM, Diagnosed Incident Cases of Gastric Cancer with MSI, Men and Women, Ages =20 Years, 2019
Figure 26: 8MM, Diagnosed Incident Cases of Gastric Cancer with NTRK Gene Fusions, Men and Women, Ages =20 Years, 2019
Figure 27: 8MM, Diagnosed Incident Cases of GEJ Cancer, Men and Women, Ages =20 Years, 2019
Figure 28: 8MM, Diagnosed Incident Cases of Gastric Cancer, Excluding GEJ Cancer, Men and Women, Ages =20 Years, 2019
Figure 29: 8MM, Diagnosed Incident Cases of Gastric Adenocarcinoma, Men and Women, Ages =20 Years, 2019
Figure 30: Treatment for G/GEJAC Patients Based on HER2 Status
Figure 31: Unmet Needs and Opportunities in G/GEJAC
Figure 32: Overview of the Development Pipeline in G/GEJAC
Figure 33: Key Late-Stage Trials for the Promising Pipeline Agents that the Publisher Expects to Be Licensed for G/GEJAC in the 8MM During the Forecast Period
Figure 34: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Chemotherapy/Chemoradiation, in the Neoadjuvant/Adjuvant Setting
Figure 35: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Herceptin, in the HER2-Positive Metastatic Setting
Figure 36: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Chemotherapy, in the HER2-Negative Metastatic Setting
\Figure 37: Analysis of the Company Portfolio Gap in G/GEJAC During the Forecast Period
Figure 38: Global (8MM) Sales Forecast by Country for G/GEJAC in 20191 and 2029
Figure 39: Sales Forecast by Class for G/GEJAC in the US in 2019 and 2029
Figure 40: Sales Forecast by Class for G/GEJAC in the 5EU in 2019 and 2021
Figure 41: Sales Forecast by Class for G/GEJAC in Japan in 2019 and 2029
Figure 42: Sales Forecast by Class for G/GEJAC in South Korea in 2019 and 2029